Evidence map›Paper›PMID 39166457›Full record

ArticleCancer medicine2024

Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning.

Qingyuan Zheng, Xinyu Wang, Rui Yang, Junjie Fan, Jingping Yuan, Xiuheng Liu, Lei Wang, Zhuoni Xiao, Zhiyuan Chen

Abstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qingyuan ZhengDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.ORCID 0000-0003-4682-3857
Xinyu WangCentre for Reproductive Science, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Rui YangDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Junjie FanUniversity of Chinese Academy of Sciences, Beijing, China.
Jingping YuanDepartment of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Xiuheng LiuDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.ORCID 0000-0003-3882-2715
Lei WangDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Zhuoni XiaoCentre for Reproductive Science, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Zhiyuan ChenDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.ORCID 0000-0002-6820-3678

Funding

Hubei Province Central Guiding Local Science and Technology Development Project 2022BGE232Hubei Province Key Research and Development Project 2020BCB051
6 · The paper itself

Abstract

backgroundTumor mutation burden (TMB) and VHL mutation play a crucial role in the management of patients with clear cell renal cell carcinoma (ccRCC), such as guiding adjuvant chemotherapy and improving clinical outcomes. However, the time-consuming and expensive high-throughput sequencing methods severely limit their clinical applicability. Predicting intratumoral heterogeneity poses significant challenges in biology and clinical settings. Our aimed to develop a self-supervised attention-based multiple instance learning (SSL-ABMIL) model to predict TMB and VHL mutation status from hematoxylin and eosin-stained histopathological images.

methodsWe obtained whole slide images (WSIs) and somatic mutation data of 350 ccRCC patients from The Cancer Genome Atlas for developing SSL-ABMIL model. In parallel, 163 ccRCC patients from Clinical Proteomic Tumor Analysis Consortium cohort was used as independent external validation set. We systematically compared three different models (Wang-ABMIL, Ciga-ABMIL, and ImageNet-MIL) for their ability to predict TMB and VHL alterations.

resultsWe first identified two groups of populations with high- and low-TMB (cut-off point = 0.9). In two independent cohorts, the Wang-ABMIL model achieved the highest performance with decent generalization performance (AUROC = 0.83 ± 0.02 and 0.8 ± 0.04 in predicting TMB and VHL, respectively). Attention heatmaps revealed that the Wang-ABMIL model paid the highest attention to tumor regions in high-TMB patients, while in VHL mutation prediction, non-tumor regions were also assigned high attention, particularly the stromal regions infiltrated by lymphocytes.

conclusionsOur results indicated that SSL-ABMIL can effectively extract histological features for predicting TMB and VHL mutation, demonstrating promising results in linking tumor morphology and molecular biology.

Indexed as

Carcinoma, Renal CellDeep LearningKidney NeoplasmsMutationVon Hippel-Lindau Tumor Suppressor ProteinAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedBiomarkers, TumorVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteinartificial intelligenceattention‐based multiple instance learningclear cell renal cell carcinomaself‐supervised learningtumor mutation burdenVHL mutation

Identifiers

PMID39166457
PMCPMC11336896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.